While the already-approved Aricept and Namenda medications have shown promise for temporarily easing symptoms, what’s desperately needed are treatments that will reverse or prevent the brain decline produced by Alzheimer’s.
Researchers are seeing promising results of the first long-term clinical trial that measured stabilization of Alzheimer’s symptoms, including thinking, memory, daily functioning and mood. The early stage results were presented at the Alzheimer’s Association International Conference in Vancouver, British Columbia, this week.
The treatment, Gammagard by Baxter, is an intravenous immune therapy that is already approved for treating other immune disorders and infections.
The small study of Gammagard included 16 subjects with mild to moderate Alzheimer’s disease who were in the first part of the trial and agreed to continue the study for three years. What’s exciting about the results of this trial is that doctors say four of the patients who continued treatment at the highest dosage showed a stop in the worsening of symptoms, making this small study the first to report symptom stabilization without decline over that longer time span. Larger studies will begin later this year.
Photos courtesy of and copyright stock.xchng, http://www.sxc.hu/